Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ganaxolone for Uncontrolled Partial-onset Seizures
NCT00465517Phase 2Completed
- Sponsor
- Marinus Pharmaceuticals
- Start
- Feb 2007
- Primary completion
- Oct 2008
- Modality
- Allosteric Modulators
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in partial epilepsy and catamenial epilepsy (CE) comparing Ganaxolone Arm with Placebo Arm (2 arms). Primary endpoint: Mean Weekly Log-transformed Seizure Frequency at 10 weeks. Started Feb 2007; status: completed.
02
Drugs
ganaxolone
03
Conditions
partial epilepsycatamenial epilepsy (CE)
Beyond the preview
Go deeper on NCT00465517.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00465517.